Concepedia

Wendy Dangerfield

WD

Statistics

Publications

7

Citations

947

H-Index

7

Active since

1999

Affiliations

Cancer Society of New Zealand(Current)

University of Auckland

UCB Pharma (United Kingdom)

Wendy Dangerfield is an author at Cancer Society of New Zealand specializing in cancer pharmacology, pharmacology, and medicine.

Publications per year

1999–2002

7

Publications

7

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Prakash Mistry, Alistair Stewart, Wendy Dangerfield et al. · PubMed · 2001 · 350 citations

, , +16

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

Michael W. Roe, Adrian Folkes, Philip J. Ashworth et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 164 citations

, , +11

Structure−Activity Relationships for Pyrido-, Imidazo-, Pyrazolo-, Pyrazino-, and Pyrrolophenazinecarboxamides as Topoisomerase-Targeted Anticancer Agents

Swarna A. Gamage, Julie A. Spicer, Gordon W. Rewcastle et al. · Journal of Medicinal Chemistry · 2002 · 147 citations

, , +10

Novel Angular Benzophenazines:  Dual Topoisomerase I and Topoisomerase II Inhibitors as Potential Anticancer Agents

Nigel Vicker, Luke Burgess, Irina Chuckowree et al. · Journal of Medicinal Chemistry · 2002 · 133 citations

, , +9

In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II

Prakash Mistry, Alistair Stewart, Wendy Dangerfield et al. · Anti-Cancer Drugs · 2002 · 62 citations

, , +15

1–5 of 7